Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: HIV Infections
Interventions: Tenofovir DF, Zidovudine, Stavudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more

Conditions: HIV, Combination Therapy
Interventions: Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more

Conditions: Herpes Simplex Type II
Interventions: TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pre-Exposure Prophylaxis
Interventions: Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV-1
Interventions: Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 84
States / cities: Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more

Conditions: HIV, STI
Interventions: PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infection
Interventions: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 73
States / cities: Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more

Conditions: Hepatitis B, Chronic
Interventions: Not listed
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 38
States / cities: Phoenix, Arizona • Garden Grove, California • Lancaster, California + 32 more

Conditions: Hypertension
Interventions: Combination pill, Ramipril; Drug
Lead sponsor: Ferrer Internacional S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis B， Chronic, Hepatitis C
Interventions: Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy; Other · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 99 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2034
U.S. locations: 2
States / cities: Baltimore, Maryland • Falls Church, Virginia

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Chronic Hepatitis B
Interventions: Tenofovir DF, FTC, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: HIV-1-infection
Interventions: Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch; Drug
Lead sponsor: Quest Clinical Research; Other
Eligibility: 45 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more

Conditions: Hepatitis C, HIV Coinfection
Interventions: TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: CHRONIC HEPATITIS B
Interventions: CTH Chronic Hepatitis B; Drug
Lead sponsor: Nguyen Thi Trieu, MD; Individual
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-1
Interventions: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more

Conditions: Chronic Hepatitis B
Interventions: RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: tenofovir, emtricitabine, atazanavir, ritonavir; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tuberculosis, Hiv
Interventions: Rifapentine daily, Rifapentine weekly; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Safety Issues
Interventions: TAF/EVG rectal insert, Matching placebo rectal insert; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 59 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Parrying the Pitfalls of PrEP: Project PEACH

Safety and Efficacy Study of Switching From Epzicom to Truvada

Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

The HOPE Study: Characterizing Patients With Hepatitis B and C

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study